Angiotech acquires Haemacure assets
This article was originally published in The Gray Sheet
Angiotech Pharmaceuticals says it will pursue commercialization of Haemacure's human biomaterial product candidates, namely fibrin sealant and thrombin hemostat, after acquiring the firm's assets in a deal announced April 7. Potential applications include general and abdominal surgery, cardiothoracic and vascular surgery, gynecology and urology surgery and reconstructive and plastic surgery. The U.S. surgical sealing and hemostat market is estimated at $500 million-plus annually, according to Angiotech. The asset sale has been authorized under Haemacure's Chapter 11 bankruptcy court proceedings. Angiotech provided Haemacure with a $2.5 million bridge loan last June, and estimates that, at closing, "it will have funded approximately $1.5 million in additional transaction-related expenses.
You may also be interested in...
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.